101. Sakai H, Tsutamoto T, Tsutsui T, et al. Serum level of uric acid, partly secreted from the failing heart, is a prognostic marker in patients with congestive
heart failure. Circ J 2006; 70: 1006-1011.
102. Kittleson MM, Bead V, Fradley M, et al. Elevated uric acid levels predict allograft vasculopathy in cardiac transplant recipients. J Heart Lung Transplant
2007; 26: 498-503.
103. Kistorp C, Faber J, Galatius S, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005; 112:
1756-1762.
104. George J, Patal S, Wexler D, et al. Circulating adiponectin concentrations in patients with congestive heart failure. Heart (British Cardiac Society) 2006;
92: 1420-1424.
105. Tsutamoto T, Tanaka T, Sakai H, et al. Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure.
Eur Heart J 2007; 28: 1723-1730.
106. 今泉勉，竹下彰．心不全 機序・病態生理 末梢循環．現代医療．1990; 22: 537-541.
107. Hirooka Y, Imaizumi T, Harada S, et al. Endotheliumdependent forearm vasodilation to acetylcholine but not to substance P is impaired in patients
with heart failure. Journal of cardiovascular pharmacology 1992; 20 Suppl. 12: S221-225.
108. Katz SD, Krum H, Khan T, et al. Exercise-induced vasodilation in forearm Circulation of normal subjects and patients with congestive heart failure:
role of endotheliumderived nitric oxide. J Am Coll Cardiol 1996; 28: 585-590.
109. Zelis R, Sinoway LI, Musch TI, et al. Regional blood flow in congestive heart failure: concept of compensatory mechanisms with short and long time
constants. Am J Cardiol 1988; 62: 2E-8E.
110. Drexler H. Changes in the peripheral Circulation in heart failure. Current opinion in cardiology 1995; 10: 268-273.
111. Kubo SH, Rector TS, Bank AJ. Endothelial nitric oxide pathway function in the peripheral vasculature of patients with heart failure. J Card Failure 1996;
2 (4 Suppl.): S217-223.
112. Mathier MA, Rose GA, Fifer MA, et al. Coronary endothelial dysfunction in patients with acute-onset idiopathic dilated cardiomyopathy. J Am Coll Cardiol
1998; 32: 216-224.
113. Katz SD, Hryniewicz K, Hriljac I, et al. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation 2005; 111:
310-314.
114. Hirooka Y, Imaizumi T, Tagawa T, et al. Effects of L-arginine on impaired acetylcholine-induced and ischemic vasodilation of the forearm in patients with
heart failure. Circulation 1994; 90: 658-668.
115. Varin R, Mulder P, Richard V, et al. Exercise improves flow-mediated vasodilatation of skeletal muscle arteries in rats with chronic heart failure. Role of
nitric oxide, prostanoids, and oxidant stress. Circulation 1999; 99: 2951-2957.
116. Mancini DM, Wilson JR, Bolinger L, et al. In vivo magnet ic resonance spect roscopy measurement of deoxymyoglobin during exercise in patients with
heart failure. Demonstration of abnormal muscle metabolism despite adequate oxygenation. Circulation 1994; 90: 500-508.
117. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on
Practice Guidelines (Committee on Evaluation and Management of Heart Failure). J Am Coll Cardiol 1995; 26: 1376-1398.
118. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart
Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed
in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009; 53: e1-e90.
119. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery:
Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing
Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): Developed in Collaboration With the
American Society of Echocardiography, American Society of Nuclear Cardiology, Hear t Rhythm Society, Society of Cardiovascular Anesthesiologists,
Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 2007;
116: 1971-1996.
120. Mancini DM, Eisen H, Kussmaul W, et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients
with heart failure. Circulation 1991; 83: 778-886.
121. Goldman L, Hashimoto B, Cook EF, et al. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a
new specific activity scale. Circulation 1981; 64: 1227-1234.
122. Sasayama S, Asanoi H, Ishizaka S. Evaluation of functional capacity of patients with congestive heart failure. In: H Y, editor. New Aspects in the Treatment
of Failing Heart Springer-Verlag 1992: 113-117.
123. Olsson LG, Swedberg K, Clark AL, et al. Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded
intervention trials of chronic heart failure: a systematic review. Eur Heart J 2005; 26: 778-793.
124. Kubozono T, Itoh H, Oikawa K, et al. Peak VO (2) is more potent than B-type natriuretic peptide as a prognostic parameter in cardiac patients. Circ J
2008; 72: 575-581.
125. Koike A, Koyama Y, Itoh H, et al. Prognostic significance of cardiopulmonary exercise testing for 10-year survival in patients with mild to moderate heart
failure. Jpn Circ J 2000; 64: 915-920.
126. Aaronson KD, Schwartz JS, Chen TM, et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred
for cardiac transplant evaluation. Circulation 1997; 95: 2660-2667.
127. Mudge GH, Goldstein S, Addonizio LJ, et al. 24th Bethesda conference: Cardiac transplantation. Task Force 3: Recipient guidelines/prioritization. J Am
Coll Cardiol 1993; 22: 21-31.
128. Gibbons RJ, Balady GJ, Beasley JW, et al. ACC/AHA Guidelines for Exercise Testing. A report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines (Committee on Exercise Testing). J Am Coll Cardiol 1997; 30: 260-311.
129. Matsumura N, Nishijima H, Kojima S, et al. Determination of anaerobic threshold for assessment of functional state in patients with chronic heart failure.
Circulation 1983; 68: 360-367.
130. Itoh H, Taniguchi K, Koike A, et al. Evaluation of severity of heart failure using ventilatory gas analysis. Circulation 1990; 81 (1 Suppl): II31-37.
131. 循環器病の診断と治療に関するガイドライン．心血管疾患におけるリハビリテーションに関するガイドライン（2007年改訂版）．http://www.j-
circ.or.jp/guideline/pdf/JCS 2007_nohara_h.pdf（2010年6月閲覧）．
132. 谷口興一，伊東春樹．心肺運動負荷テストと運動療法．南江堂 2004.
133. Weber KT, Janicki JS. Cardiopulmonary exercise testing for evaluation of chronic cardiac failure. Am J Cardiol 1985; 55: 22A-31A.
134. Wasserman K, Hansen J, Sue D. Physiology of Exercise. Principles of Exercise Testing and Interpretation: Lea & Febiger 1994: 9-51.
135. Koike A, Hiroe M, Adachi H, et al. Cardiac output-O2 uptake relation during incremental exercise in patients with previous myocardial infarction.
Circulation 1992; 85: 1713-1719.
136. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003; 167: 211-277.
137. 村山正博．1990年度報告，日本人の運動呼吸循環指標 の標準値．Jpn Circl J 1992: 1514-1523.
138. Weber K, Janicki J, McElroy P. Cardiopulmonary exercise (CPX) testing .In : Weber K, Janicki J, editors. Cardiopulmonary Exercise Testing: W. B.
Saunders Company 1986: 151-167.
139. Ogawa T, Spina RJ, Martin WH, 3rd, et al. Effects of aging, sex, and physical training on cardiovascular responses to exercise. Circulation 1992; 86:
494-503.
140. Lipkin DP, Scriven AJ, Crake T, et al. Six minute walking test for assessing exercise capacity in chronic heart failure. British medical journal (Clinical
research ed. 1986; 292: 653-655.
141. 大西洋三，佐藤秀幸，是恒之宏．6分間歩行試験の正常値の分布とその規定因子に関する検討．Jpn Circl J 1998.
142. McAlister FA, Stewart S, Ferrua S, et al. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a
systematic review of randomized trials. J Am Coll Cardiol 2004; 44: 810-819.
143. Kato N, Kinugawa K, Ito N, et al. Adherence to self-care behavior and factors related to this behavior among patients with heart failure in Japan. Heart
Lung 2009; 38: 398-409.
144. Kato N, Ito N, Kinugawa K, et al. Validity and reliability of the Japanese version of the European Heart Failure Self-Care Behavior Scale. Eur J
Cardiovasc Nurs 2008; 7: 284-289.
145. Tsuchihashi M, Tsutsui H, Kodama K, et al. Clinical characteristics and prognosis of hospitalized patients with congestive heart failure--a study in
Fukuoka, Japan. Jpn Cire J 2000; 64: 953-959.
146. 筒井裕之．絵でわかる心不全患者さんのためのいきいき生活ガイド．ライフサイエンス社 2009.
147. Konstam MA, Dracup K, Baker DW, et al. Heart failure: evaluation and care of patients with left ventricular systolic dysfunction. J Card Failure 1995; 1:
183-187.
148. de Diego C, Vila-Corcoles A, Ochoa O, et al. Effects of annual influenza vaccination on winter mortality in elderly people with chronic heart disease.
Eur Heart J 2009; 30: 209-216.
149. Evangelista LS, Doering LV, Dracup K. Usefulness of a history of tobacco and alcohol use in predicting multiple heart failure readmissions among
veterans. Am J Cardiol 2000; 86: 1339-1342.
150. Suskin N, Sheth T, Negassa A, et al. Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction.
J Am Coll Cardiol 2001; 37: 1677-1682.
151. 斎藤宗靖，後藤葉一編集．狭心症・心筋梗塞のリハビリテーション．高齢患者の心臓リハビリテーションにおける理学療法士の役割 2009: 312-313.
152. Piepoli MF, Davos C, Francis DP, et al. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ (Clinical
research ed.) 2004; 328: 189.
153. Sullivan MJ, Higginbotham MB, Cobb FR. Exercise training in patients with severe left ventricular dysfunction. Hemodynamic and metabolic effects.
Circulation 1988; 78: 506-515.
154. Tei C, Horikiri Y, Park JC, et al. Acute hemodynamic improvement by thermal vasodilation in congestive heart failure. Circulation 1995; 91: 2582-2590.
155. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial
infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Eng J Med 1992; 327: 669-677.
156. Johnston BL, Fletcher GF. Dynamic electrocardiographic recording during sexual activity in recent post-myocardial infarction and revascularization
patients. Am Heart J 1979; 98: 736-741.
157. Bocchi EA, Guimaraes G, Mocelin A, et al. Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart
failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 2002; 106:
1097-1103.
158. Lewis GD, Lachmann J, Camuso J, et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure.
Circulation 2007; 115: 59-66.
159. Tsuchihashi-Makaya M, Kato N, Chishaki A, et al. Anxiety and poor social support are independently associated with adverse outcomes in patients
with mild heart failure. Circ J 2009; 73: 280-287.
160. Kato N, Kinugawa K, Yao A, et al. Relationship of depressive symptoms with hospitalization and death in Japanese patients with heart failure. J
Card Failure 2009; 15: 912-919.
161. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999 Jan 2; 353: 9-13.
162. Garg R, Gorlin R, Smith T, et al. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Eng
J Med 1997; 336: 525-533.
163. Tsuchihashi M, Tsutsui H, Kodama K, et al. Medical and socioenvironmental predictors of hospital readmission in patients with congestive heart
failure. Am Heart J 2001; 142: E7.
164. Jaarsma T, Stewart S. Nurse-led management programmes in heart failure. Caring for the heart failure patients 2004: 169.
165. Moser DK, Riegel B. Management of heart failure in the outpatient setting. Heart failure 2004: 772.
166. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289: 871-878.
167. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Eng J Med 2002; 347: 1403-1411.
168. Ahmed A, Husain A, Love TE, et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity
score methods. Eur Heart J 2006; 27: 1431-1439.
169. Gheorghiade M, Konstam MA, Burnett JC, Jr., et al. Shortterm clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for
heart failure: the EVEREST Clinical Status Trials. JAMA 2007; 297: 1332-1343.
170. Konstam MA, Gheorghiade M, Burnett JC, Jr., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome
Trial. JAMA 2007; 297: 1319-1331.
171. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).
The CONSENSUS Trial Study Group. N Eng J Med 1987; 316: 1429-1435.
172. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD
Investigattors. N Eng J Med 1992; 327: 685-691.
173. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Eng J
Med 1991; 325: 293-302.
174. Jong P, Yusuf S, Rousseau MF, et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a
follow-up study. Lancet 2003; 361: 1843-1848.
175. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensinconverting enzyme inhibitor, lisinopril, on
morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100: 2312-2318.
176. Matsumori A. Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur J Heart Fail 2003; 5: 669-677.
177. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function
intolerant to angiotensinconverting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772-776.
178. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised
trial--the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-1587.
179. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular
dysfunction, or both. N Eng J Med 2003; 349: 1893-1906.
180. Cohn JN, Tognoni G. A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Eng J Med 2001; 345: 1667-1675.
181. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic
function taking angiotensinconverting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-771.
182. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart
Failure Study Group. N Eng J Med 1996; 334: 1349-1355.
183. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet
1999; 353: 2001-2007.
184. Hori M, Sasayama S, Kitabatake A, et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese
patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 2004; 147: 324-330.
185. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Eng J Med 2001; 344: 1651-1658.
186. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in
the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362: 7-13.
187. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
Lancet. 2001; 357: 1385-1390.
188. Yoshizawa A, Yoshikawa T, Nakamura I, et al. Brain natriuretic peptide response is heterogeneous during beta-blocker therapy for congestive heart
failure. J Card Failure 2004; 10: 310-315.
189. Gattis WA, O’Connor CM, Gallup DS, et al. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of
the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol 2004;
43: 1534-1541.
190. Metra M, Nodari S, D’Aloia A, et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a
randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol 2002; 40:
1248-1258.
191. Fonarow GC, Abraham WT, Albert NM, et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure:
findings from the OPTIMIZE-HF program. J Am Coll Cardiol 2008; 52: 190-199.
192. Liggett SB, Cresci S, Kelly RJ, et al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med 2008;
14: 510-517.
193. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al. A polymorphism within a conserved beta (1)-adrenergic receptor motif alters cardiac function and
beta-blocker response in human heart failure. Proc Natl Acad Sci U S A 2006; 103: 11288-11293.
194. Willenheimer R, van Veldhuisen DJ, Silke B, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol
followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation
2005; 112: 2426-2435.
195. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Eng J Med 2004; 351:
543-551.
196. Massie BM, Fisher SG, Radford M, et al. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure.
CHF-STAT Investigators. Circulation 1996; 93: 2128-2134.
197. Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en
la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 1994; 344: 493-498.
198. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: metaanalysis of individual data from 6500
patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet 1997; 350: 1417-1424.
199. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Eng J Med 2005; 352: 225-237.
200. Packer M, O’Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized
Amlodipine Survival Evaluation Study Group. N Eng J Med 1996; 335: 1107-1114.
heart failure. Circ J 2006; 70: 1006-1011.
102. Kittleson MM, Bead V, Fradley M, et al. Elevated uric acid levels predict allograft vasculopathy in cardiac transplant recipients. J Heart Lung Transplant
2007; 26: 498-503.
103. Kistorp C, Faber J, Galatius S, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005; 112:
1756-1762.
104. George J, Patal S, Wexler D, et al. Circulating adiponectin concentrations in patients with congestive heart failure. Heart (British Cardiac Society) 2006;
92: 1420-1424.
105. Tsutamoto T, Tanaka T, Sakai H, et al. Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure.
Eur Heart J 2007; 28: 1723-1730.
106. 今泉勉，竹下彰．心不全 機序・病態生理 末梢循環．現代医療．1990; 22: 537-541.
107. Hirooka Y, Imaizumi T, Harada S, et al. Endotheliumdependent forearm vasodilation to acetylcholine but not to substance P is impaired in patients
with heart failure. Journal of cardiovascular pharmacology 1992; 20 Suppl. 12: S221-225.
108. Katz SD, Krum H, Khan T, et al. Exercise-induced vasodilation in forearm Circulation of normal subjects and patients with congestive heart failure:
role of endotheliumderived nitric oxide. J Am Coll Cardiol 1996; 28: 585-590.
109. Zelis R, Sinoway LI, Musch TI, et al. Regional blood flow in congestive heart failure: concept of compensatory mechanisms with short and long time
constants. Am J Cardiol 1988; 62: 2E-8E.
110. Drexler H. Changes in the peripheral Circulation in heart failure. Current opinion in cardiology 1995; 10: 268-273.
111. Kubo SH, Rector TS, Bank AJ. Endothelial nitric oxide pathway function in the peripheral vasculature of patients with heart failure. J Card Failure 1996;
2 (4 Suppl.): S217-223.
112. Mathier MA, Rose GA, Fifer MA, et al. Coronary endothelial dysfunction in patients with acute-onset idiopathic dilated cardiomyopathy. J Am Coll Cardiol
1998; 32: 216-224.
113. Katz SD, Hryniewicz K, Hriljac I, et al. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation 2005; 111:
310-314.
114. Hirooka Y, Imaizumi T, Tagawa T, et al. Effects of L-arginine on impaired acetylcholine-induced and ischemic vasodilation of the forearm in patients with
heart failure. Circulation 1994; 90: 658-668.
115. Varin R, Mulder P, Richard V, et al. Exercise improves flow-mediated vasodilatation of skeletal muscle arteries in rats with chronic heart failure. Role of
nitric oxide, prostanoids, and oxidant stress. Circulation 1999; 99: 2951-2957.
116. Mancini DM, Wilson JR, Bolinger L, et al. In vivo magnet ic resonance spect roscopy measurement of deoxymyoglobin during exercise in patients with
heart failure. Demonstration of abnormal muscle metabolism despite adequate oxygenation. Circulation 1994; 90: 500-508.
117. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on
Practice Guidelines (Committee on Evaluation and Management of Heart Failure). J Am Coll Cardiol 1995; 26: 1376-1398.
118. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart
Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed
in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009; 53: e1-e90.
119. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery:
Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing
Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): Developed in Collaboration With the
American Society of Echocardiography, American Society of Nuclear Cardiology, Hear t Rhythm Society, Society of Cardiovascular Anesthesiologists,
Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 2007;
116: 1971-1996.
120. Mancini DM, Eisen H, Kussmaul W, et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients
with heart failure. Circulation 1991; 83: 778-886.
121. Goldman L, Hashimoto B, Cook EF, et al. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a
new specific activity scale. Circulation 1981; 64: 1227-1234.
122. Sasayama S, Asanoi H, Ishizaka S. Evaluation of functional capacity of patients with congestive heart failure. In: H Y, editor. New Aspects in the Treatment
of Failing Heart Springer-Verlag 1992: 113-117.
123. Olsson LG, Swedberg K, Clark AL, et al. Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded
intervention trials of chronic heart failure: a systematic review. Eur Heart J 2005; 26: 778-793.
124. Kubozono T, Itoh H, Oikawa K, et al. Peak VO (2) is more potent than B-type natriuretic peptide as a prognostic parameter in cardiac patients. Circ J
2008; 72: 575-581.
125. Koike A, Koyama Y, Itoh H, et al. Prognostic significance of cardiopulmonary exercise testing for 10-year survival in patients with mild to moderate heart
failure. Jpn Circ J 2000; 64: 915-920.
126. Aaronson KD, Schwartz JS, Chen TM, et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred
for cardiac transplant evaluation. Circulation 1997; 95: 2660-2667.
127. Mudge GH, Goldstein S, Addonizio LJ, et al. 24th Bethesda conference: Cardiac transplantation. Task Force 3: Recipient guidelines/prioritization. J Am
Coll Cardiol 1993; 22: 21-31.
128. Gibbons RJ, Balady GJ, Beasley JW, et al. ACC/AHA Guidelines for Exercise Testing. A report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines (Committee on Exercise Testing). J Am Coll Cardiol 1997; 30: 260-311.
129. Matsumura N, Nishijima H, Kojima S, et al. Determination of anaerobic threshold for assessment of functional state in patients with chronic heart failure.
Circulation 1983; 68: 360-367.
130. Itoh H, Taniguchi K, Koike A, et al. Evaluation of severity of heart failure using ventilatory gas analysis. Circulation 1990; 81 (1 Suppl): II31-37.
131. 循環器病の診断と治療に関するガイドライン．心血管疾患におけるリハビリテーションに関するガイドライン（2007年改訂版）．http://www.j-
circ.or.jp/guideline/pdf/JCS 2007_nohara_h.pdf（2010年6月閲覧）．
132. 谷口興一，伊東春樹．心肺運動負荷テストと運動療法．南江堂 2004.
133. Weber KT, Janicki JS. Cardiopulmonary exercise testing for evaluation of chronic cardiac failure. Am J Cardiol 1985; 55: 22A-31A.
134. Wasserman K, Hansen J, Sue D. Physiology of Exercise. Principles of Exercise Testing and Interpretation: Lea & Febiger 1994: 9-51.
135. Koike A, Hiroe M, Adachi H, et al. Cardiac output-O2 uptake relation during incremental exercise in patients with previous myocardial infarction.
Circulation 1992; 85: 1713-1719.
136. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003; 167: 211-277.
137. 村山正博．1990年度報告，日本人の運動呼吸循環指標 の標準値．Jpn Circl J 1992: 1514-1523.
138. Weber K, Janicki J, McElroy P. Cardiopulmonary exercise (CPX) testing .In : Weber K, Janicki J, editors. Cardiopulmonary Exercise Testing: W. B.
Saunders Company 1986: 151-167.
139. Ogawa T, Spina RJ, Martin WH, 3rd, et al. Effects of aging, sex, and physical training on cardiovascular responses to exercise. Circulation 1992; 86:
494-503.
140. Lipkin DP, Scriven AJ, Crake T, et al. Six minute walking test for assessing exercise capacity in chronic heart failure. British medical journal (Clinical
research ed. 1986; 292: 653-655.
141. 大西洋三，佐藤秀幸，是恒之宏．6分間歩行試験の正常値の分布とその規定因子に関する検討．Jpn Circl J 1998.
142. McAlister FA, Stewart S, Ferrua S, et al. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a
systematic review of randomized trials. J Am Coll Cardiol 2004; 44: 810-819.
143. Kato N, Kinugawa K, Ito N, et al. Adherence to self-care behavior and factors related to this behavior among patients with heart failure in Japan. Heart
Lung 2009; 38: 398-409.
144. Kato N, Ito N, Kinugawa K, et al. Validity and reliability of the Japanese version of the European Heart Failure Self-Care Behavior Scale. Eur J
Cardiovasc Nurs 2008; 7: 284-289.
145. Tsuchihashi M, Tsutsui H, Kodama K, et al. Clinical characteristics and prognosis of hospitalized patients with congestive heart failure--a study in
Fukuoka, Japan. Jpn Cire J 2000; 64: 953-959.
146. 筒井裕之．絵でわかる心不全患者さんのためのいきいき生活ガイド．ライフサイエンス社 2009.
147. Konstam MA, Dracup K, Baker DW, et al. Heart failure: evaluation and care of patients with left ventricular systolic dysfunction. J Card Failure 1995; 1:
183-187.
148. de Diego C, Vila-Corcoles A, Ochoa O, et al. Effects of annual influenza vaccination on winter mortality in elderly people with chronic heart disease.
Eur Heart J 2009; 30: 209-216.
149. Evangelista LS, Doering LV, Dracup K. Usefulness of a history of tobacco and alcohol use in predicting multiple heart failure readmissions among
veterans. Am J Cardiol 2000; 86: 1339-1342.
150. Suskin N, Sheth T, Negassa A, et al. Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction.
J Am Coll Cardiol 2001; 37: 1677-1682.
151. 斎藤宗靖，後藤葉一編集．狭心症・心筋梗塞のリハビリテーション．高齢患者の心臓リハビリテーションにおける理学療法士の役割 2009: 312-313.
152. Piepoli MF, Davos C, Francis DP, et al. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ (Clinical
research ed.) 2004; 328: 189.
153. Sullivan MJ, Higginbotham MB, Cobb FR. Exercise training in patients with severe left ventricular dysfunction. Hemodynamic and metabolic effects.
Circulation 1988; 78: 506-515.
154. Tei C, Horikiri Y, Park JC, et al. Acute hemodynamic improvement by thermal vasodilation in congestive heart failure. Circulation 1995; 91: 2582-2590.
155. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial
infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Eng J Med 1992; 327: 669-677.
156. Johnston BL, Fletcher GF. Dynamic electrocardiographic recording during sexual activity in recent post-myocardial infarction and revascularization
patients. Am Heart J 1979; 98: 736-741.
157. Bocchi EA, Guimaraes G, Mocelin A, et al. Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart
failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 2002; 106:
1097-1103.
158. Lewis GD, Lachmann J, Camuso J, et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure.
Circulation 2007; 115: 59-66.
159. Tsuchihashi-Makaya M, Kato N, Chishaki A, et al. Anxiety and poor social support are independently associated with adverse outcomes in patients
with mild heart failure. Circ J 2009; 73: 280-287.
160. Kato N, Kinugawa K, Yao A, et al. Relationship of depressive symptoms with hospitalization and death in Japanese patients with heart failure. J
Card Failure 2009; 15: 912-919.
161. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999 Jan 2; 353: 9-13.
162. Garg R, Gorlin R, Smith T, et al. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Eng
J Med 1997; 336: 525-533.
163. Tsuchihashi M, Tsutsui H, Kodama K, et al. Medical and socioenvironmental predictors of hospital readmission in patients with congestive heart
failure. Am Heart J 2001; 142: E7.
164. Jaarsma T, Stewart S. Nurse-led management programmes in heart failure. Caring for the heart failure patients 2004: 169.
165. Moser DK, Riegel B. Management of heart failure in the outpatient setting. Heart failure 2004: 772.
166. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289: 871-878.
167. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Eng J Med 2002; 347: 1403-1411.
168. Ahmed A, Husain A, Love TE, et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity
score methods. Eur Heart J 2006; 27: 1431-1439.
169. Gheorghiade M, Konstam MA, Burnett JC, Jr., et al. Shortterm clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for
heart failure: the EVEREST Clinical Status Trials. JAMA 2007; 297: 1332-1343.
170. Konstam MA, Gheorghiade M, Burnett JC, Jr., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome
Trial. JAMA 2007; 297: 1319-1331.
171. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).
The CONSENSUS Trial Study Group. N Eng J Med 1987; 316: 1429-1435.
172. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD
Investigattors. N Eng J Med 1992; 327: 685-691.
173. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Eng J
Med 1991; 325: 293-302.
174. Jong P, Yusuf S, Rousseau MF, et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a
follow-up study. Lancet 2003; 361: 1843-1848.
175. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensinconverting enzyme inhibitor, lisinopril, on
morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100: 2312-2318.
176. Matsumori A. Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur J Heart Fail 2003; 5: 669-677.
177. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function
intolerant to angiotensinconverting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772-776.
178. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised
trial--the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-1587.
179. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular
dysfunction, or both. N Eng J Med 2003; 349: 1893-1906.
180. Cohn JN, Tognoni G. A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Eng J Med 2001; 345: 1667-1675.
181. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic
function taking angiotensinconverting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-771.
182. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart
Failure Study Group. N Eng J Med 1996; 334: 1349-1355.
183. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet
1999; 353: 2001-2007.
184. Hori M, Sasayama S, Kitabatake A, et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese
patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 2004; 147: 324-330.
185. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Eng J Med 2001; 344: 1651-1658.
186. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in
the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362: 7-13.
187. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
Lancet. 2001; 357: 1385-1390.
188. Yoshizawa A, Yoshikawa T, Nakamura I, et al. Brain natriuretic peptide response is heterogeneous during beta-blocker therapy for congestive heart
failure. J Card Failure 2004; 10: 310-315.
189. Gattis WA, O’Connor CM, Gallup DS, et al. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of
the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol 2004;
43: 1534-1541.
190. Metra M, Nodari S, D’Aloia A, et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a
randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol 2002; 40:
1248-1258.
191. Fonarow GC, Abraham WT, Albert NM, et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure:
findings from the OPTIMIZE-HF program. J Am Coll Cardiol 2008; 52: 190-199.
192. Liggett SB, Cresci S, Kelly RJ, et al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med 2008;
14: 510-517.
193. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al. A polymorphism within a conserved beta (1)-adrenergic receptor motif alters cardiac function and
beta-blocker response in human heart failure. Proc Natl Acad Sci U S A 2006; 103: 11288-11293.
194. Willenheimer R, van Veldhuisen DJ, Silke B, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol
followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation
2005; 112: 2426-2435.
195. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Eng J Med 2004; 351:
543-551.
196. Massie BM, Fisher SG, Radford M, et al. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure.
CHF-STAT Investigators. Circulation 1996; 93: 2128-2134.
197. Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en
la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 1994; 344: 493-498.
198. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: metaanalysis of individual data from 6500
patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet 1997; 350: 1417-1424.
199. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Eng J Med 2005; 352: 225-237.
200. Packer M, O’Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized
Amlodipine Survival Evaluation Study Group. N Eng J Med 1996; 335: 1107-1114.
文献
慢性心不全治療ガイドライン（2010年改訂版）
Guidelines for Treatment of Chronic Heart Failure（JCS 2010）
Guidelines for Treatment of Chronic Heart Failure（JCS 2010）